This inspired a phase I study combining IL-2 and SBRT for patients with metastatic renal cell carcinoma and melanoma in which 2/3 of the patients demonstrated a response, and immune-monitoring looking at cryopreserved PMBCs showed a significantly greater frequency of proliferating CD4+ T cells with an early activated effector memory phenotype (158). Here, IL2 is linked to melanoma.